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Summary
An increasing morbidity of atopic diseases (atopic dermatitis, food allergy, asthma and allergic 
rhinitis) documented in large cohort epidemiological studies is at least partially determined 
by high hygienic standards of living. Over the last 40 years, the accepted concept of patho-
genesis of atopic diseases, the so-called atopic march, was proposed by Fouchard in 1973. It 
referred to the natural history of atopy manifestation, with a typical sequence of symptoms 
presented as atopic dermatitis in early childhood for subsequent development of allergic 
respiratory symptoms in late childhood and adolescence. New data suggests that the leading 
role of atopic dermatitis in atopic march might be less pronounced than previously expec-
ted, indicating coexistence rather than succession of atopic symptoms. The objective of this 
paper is to present the currently discussed concepts of atopic dermatitis – its pathogenesis, 
etiology, course and role in the development of other allergic diseases. More widely, we will 
present: 1. The genetic factors involved in skin barrier disruption with the leading role of 
loss-of-function gene for filaggrin mutation, 2. Genetic defects and epigenetic regulation of 
the immune system 3. Epidermal changes with physical barrier dysfunction as well as 4. Skin 
microbiome disturbances with Staphylococcus aureus colonization leading to abnormalities 
of the epidermal protective barrier.
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IntroductIon
Allergic diseases belong to the most common chronic 
diseases of childhood and adolescence and are there-
fore becoming an ever-increasing challenge for modern 
medicine. An increasing morbidity of atopic diseases as 
atopic dermatitis (AD), food allergy, asthma and aller-
gic rhinitis (AR) are at least partially determined by 
high hygienic standards of living and modern life-style 
[58,66]. The most extensive epidemiological study evalu-
ating the allergic disease incidence in the Polish popu-
lation is ECAP (Epidemiology of Allergic Diseases in 
Poland; www.ecap.pl). The study was based on the same 
methodology as the International Study of Asthma and 
Allergy in Childhood (ISAAC) and European Community 
Respiratory Health Survey II (ECRHS II) [55]. The inci-
dence of allergic diseases following verification by medi-
cal examinations in children aged 6-7 years, adolescents 
aged 13-14 years and adults aged 22-40 years was 40%, 
43% and 39%, respectively [4]. Although in the studied 
population, the AD prevalence was lower than the mean 
European incidence (3.91% vs. 20%), the profile of risk 
factors (female sex, high social-economic status, paren-
tal history of atopy, living in a city) was similar to the 
data originating from other European countries [19,60]. 
A high allergic diseases morbidity was also reflected in 
the data from two longitudinal prospective epidemiolo-
gical studies performed in large cohorts of British chil-
dren: Avon Longitudinal Study of Parents and Children 
(ALSPAC – 8665 children) and Manchester Asthma and 
Allergy Study (MAAS – 1136 children) [12], where, in the 
group of children investigated from birth to 11 years 
of age, 48.7% reported one of the following symptoms: 
eczema, expiratory wheeze or rhinitis. Such a common 
occurrence of allergic diseases necessitates a search for 
their causes, a determination of their natural course and 
possible preventive measures.
Over the last 40 years, the predominating concept 
explaining this phenomenon focused on the so-cal-
led atopic march, based on the evolution of organ-
-related manifestations of allergy in children. The 
term was proposed by Fouchard in 1973 and referred 
to the natural history of atopic diseases, with a typi-
cal sequence of serial symptoms presented from early 
to late childhood and adolescence: food allergy→atopic 
dermatitis→asthma→allergic rhinitis. In keeping with 
the hypothesis, AD symptoms in early childhood (up to 
2 years of age) constituted a triggering factor and pre-
dictor of asthma and AR in later childhood. The validity 
of the atopic march idea was suggested by the results of 
numerous population studies based on correct metho-
dology (prospective studies) and large cohorts [22,50]. 
The data based on joint results of MAAS and ALSPAC 
studies throw a new light on the current concept [12]. 
Authors selected eight possible phenotypes of sequ-
ential AD – eczema, wheezing and rhinitis. The classic 
sequence of atopic march was followed only by 3.1% 
of the respondents [12]. Even when a separate analysis 
of MAAS data included only children with moderate to 
severe AD symptoms, the percentage of those manife-
sting symptoms chronology typical for the atopic march 
increased only to 7%. Currently, four clinical phenoty-
pes of AD are identified: 1. Early onset and low atopy 
grade, 2. Early onset, high atopy grade and high eosi-
nophilia, 3. Late onset and low atopy grade, and 4. Late 
onset, high atopy grade and normal eosinophil count. 
Only the second phenotype shows an association with 
the atopic march, manifested as bronchial hyperreacti-
vity and asthma [41]. Early AD onset (below 6 months 
of age) seems to be familial (parental atopy), while late 
AD development (above 12 months of age) is affected 
by antibiotic therapy administered before the end of 6 
months of life [45]. In the cohort of prospective ORCA 
(Observatory of Respiratory risks linked with Cutane-
ous Atopy) study conducted in 2002-2012, children with 
early-onset AD were grouped in two phenotypes: 39% 
demonstrated multiple sensitization to different food 
and inhalant allergens, in 17%, symptoms were strongly 
associated with familial asthma history, while 44% pre-
sented no atopic disease in later life [3].
The above reports prompt an analysis of AD anew from 
a broader perspective. The objective of the paper is to 
present the currently discussed concepts of AD patho-
genesis and etiology, its course and role in development 
of other allergic diseases.
Ad pAthogenesIs
In light of contemporary knowledge, the etiology and 
pathogenesis of AD result from genetic and environmen-
tal factors. Both groups of factors determine epidermal 
lesions and affect the immune system balance, initiating 
the vicious circle of negative phenomena initially loca-
ted in the skin, which, under favorable conditions, may 
also involve remote tissues and organs (Figure 1) [28].
genetIc fActors Involved In skIn bArrIer dIsruptIon
Genetic factors involved in the disruption of skin barrier 
function are associated with the locus on chromosome 
1q21, the so-called epidermal differentiation complex 
(EDC) [18]. It includes a gene family that encodes pro-
teins, such as loricrin (LOR), involucrin (IVL) and the 
most significant – filaggrin (FLG) [7]. In the Caucasian 
factor, ORCA study – Observatory of Respiratory risks linked with Cutaneous Atopy study, PRRs 
– pattern recognition receptors, S. – Staphylococcus, SC – stratum corneum, SEB – staphylococcal 
enterotoxin B, SPINK5/LEKTI – serine protease inhibitor Kazal-type 5/lympho-epithelial Kazal-ty-
pe-related inhibitor, TCR – T Cell Receptor, TEWL – transepithelial water loss, TJs – tight junctions, 
TSLP – thymic stromal lymphopoietin
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genetIc fActors In Immune skIn bArrIer
The most important candidates include genes associ-
ated with the Toll-like receptor 2 (TLR2), Toll-like recep-
tor 9 (TLR9), IL4, IL13 and IL31 cytokines, alpha chain 
of the IL-4 receptor (IL4RA) and high affinity IgE recep-
tor (FcεRI) [7,13]. The TLR are a link between the aller-
gic march concept and the so-called hygienic theory, 
since transcutaneous exposure to bacterial lipopoly-
saccharides (LPS) shifts the Th1/Th2 balance towards 
Th1, stimulates INF-gamma synthesis and supports the 
protective role of the skin microbiome in allergic dis-
eases development [30]. Restricting the exposure to LPS 
resulting from high hygiene standards shifts the balance 
towards the Th2 phenotype and favors atopic disease 
manifestation [67].
Regardless of the well-defined genetic defects, an 
increasing role is ascribed to the epigenetic regulation 
of the immune system activity, affected by environ-
mental factors [31]. The so-called cofactors affect the 
population, approximately 1/3 of AD patients carry two 
most common FLG loss-of-function mutations – R501X 
and 2282del4 [9], in the general European population, 
the above variants are found in 9% of the investigated 
subjects [52]. According to ECAP, in the Polish general 
population, the incidence of the mutations is low (0.8% 
and 3.67%, respectively) [53]. FLG mutation causes more 
than a three-fold increase of AD risk [5]. In FLG loss-of-
function mutation carriers, AD is characterized by early 
onset and a severe, chronic course (Table 1) [25, 47]. Also, 
according to ECAP, carrying FLG mutation increases the 
risk of AD, AR and atopic asthma [53].
Other genes associated with epidermal dysfunctions are 
the serine protease inhibitor Kazal-type 5/lympho-ep-
ithelial Kazal-type-related inhibitor (SPINK5/LEKTI) 
encoding gene (defective in Netherton syndrome with 
an autosomal recessive pattern of inheritance) [32] and 
claudins-encoding genes (such as CLDN 1, CLDN 4) – 
tight junction adhesion proteins in epidermal cells [7].
Fig. 1. A scheme of pathophysiological reactions observed in acute and chronic AD (own modification based on [28]);FLG – filaggrin; IVL – involucrin; LOR – loricrin; 
CLDN – claudin; SPINK5/LEKTI – serine protease inhibitor Kazal-type 5; TLR – Toll-like receptor; IL4RA – interleukin-4 receptor alfa chain; FcεRI – the high-affinity receptor 
for the Fc region of immunoglobulin E; NMF – natural moisturizing factor; TEWL – transepidermal water loss;  AMPs – antimicrobial peptides; DAMPs – damage-
associated molecular patterns; TJs – tight junctions; TSLP – thymic stromal lymphopoietin; LCs – Langerhans cells; SEB – Staphylococcal enterotoxin B
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mining keratinocyte flattening in the outermost skin 
layer [43]. FLG decomposition products together with 
chloride and sodium ions, lactic acid and urea form a nat-
ural moisturizing factor (NMF) for SC and maintain low 
pH with its antibacterial function and beneficial effect on 
ceramide-metabolizing enzymes [15]. AD skin is charac-
terized by intensified transepithelial water loss (TEWL) 
and abnormal final keratinocyte differentiation process, 
which leads to decreased contents of ceramides, FLG and 
antimicrobial peptides (AMPs) [43]. Another significant 
element determining the physical integrity of the epi-
dermal barrier are protein-formed (the major types are 
the claudins and the occludins) so-called tight junctions 
(TJs), situated in the epidermal layers below SC [43]. Their 
role is to stabilize intercellular junctions, to maintain cell 
polarization and to control solute flow through intercel-
lular space [20]. AD patients manifest decreased levels of 
claudine-1 (CLDN1) and claudine-23 (CLDN23) [8, 20]. In 
an animal model, CLDN1-deficient mice died at approxi-
mately 24 days of life due to severe dehydration resulting 
from intensified transepithelial water loss (TEWL) [26]. In 
infants, intensified TEWL on the second day and in the 
second month of life is of a prognostic value for AD occur-
rence at 12 months of age [34], and its degree is correlated 
with the degree of allergy to inhalant allergens [21]. Also, 
decreased expression of occludins was identified in the 
nasal epithelium of patients with allergic rhinitis allergic 
to house dust mites [59].
Immune dIsturbAnces In Ad – the vIcIous cIrcle mechAnIsm
The skin barrier plays a significant protective role. It is 
the first line of defense, the site where the immune sys-
tem comes in contact with the external environment.
“silencing” gene mechanisms and thus may affect their 
unblocking and activation. The best known epigene-
tic processes include DNA methylation, usually leading 
to gene silencing via transcription inhibition [31] and 
post-translational histone modifications, resulting in 
chromatin loosening (active euchromatin) or condens-
ing (inactive heterochromatin), and thus respectively 
affecting upregulated or downregulated gene expres-
sion [11]. Although each cell expresses the identical 
DNA sequence, from the epigenetic viewpoint, further 
differentiation and cell activation is possible due to the 
above mechanisms [31]. For example, a shift in the bal-
ance towards Th2 lymphocytes results from a simulta-
neous activation of the T Cell Receptor (TCR) and IL-4 
receptor, while the IL-4 gene expression in case of aller-
gen-specific T lymphocytes results from IL-4 promoter 
demethylation [39]. Numerous environmental factors 
have been identified – allergens, microorganisms and 
LPSs, tobacco smoke, folic acid supplementation, that 
determine development of a given atopic disease via 
epigenetic activity (Table 2). Moreover, increasing evi-
dence indicates the inheritance of epigenetic changes 
and their persistence in subsequent generations [11].
epIdermAl chAnges – physIcAl bArrIer defects – role of 
fIlAggrIn And tIght junctIons
The stratum corneum (SC) is the site where normally 
differentiated keratinocytes are responsible for produc-
ing a lipid-protein matrix playing the role of a physical 
protective barrier, preventing water loss and protecting 
against allergens and microorganisms [43]. The main pro-
tein produced by keratinocytes is FLG, the role of which 
consists in aggregating the keratin cytoskeleton, deter-
Table 1. Comparison of the clinical and biochemical features of patients with ADFLG and patients with ADNON-FLG  (based on [48])
Features ADFLG ADNON-FLG
Clinical
Palmar hyperlinearity Present Absent
Durability and intensity More severe and persistent Less persistent
Risk of asthma High Low
Allergic sensitization Often present Rarely or not
Eczema herpeticum Often present Rarely or no
Biophysical
NMF ↓↓ ↓
pH ↑ lower compared to ADFLG
IL–1β ↑ lower compared to ADFLG
NMF (natural moisturising factor)
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and is present in nonlesional skin, whereas TH22 – and 
TH1-driven inflammation is prominent in patients with 
the chronic form of AD. [28,49].
skIn mIcrobIome dIsturbAnces In Ad
The term microbiome includes the total of microor-
ganisms that occasionally or permanently colonize the 
superficial skin layers. The composition of skin-coloniz-
ing microorganisms depends on its current condition and 
maturity [10]. In seborrheic regions, Propionibacterium 
and Staphylococcus sp. bacteria predominate, regions 
with increased humidity abound in Corynebacterium 
sp., while in dry skin areas, the flora is the most diversi-
fied [29]. A different skin microbiome is seen in an infant, 
which results from skin structural and functional imma-
turity and becomes similar to that of an adult when the 
child is one year old [10]. In the case of Cesarean deliver-
ies, from the beginning, the neonatal skin becomes col-
onized with microorganisms bacteria living on maternal 
skin (i.e. Staphylococcus, Propionibacterium and Coryne-
bacterium sp.) [23]. Staphylococcus (S.) epidermidis is the 
dominant commensal bacterium permanently coloniz-
ing the human skin, having the ability to release proteins 
with activity similar to that of AMPs produced by kera-
tinocytes and thus inhibiting skin colonization by such 
pathogens as Staphylococcus aureus, group A streptococci 
and Escherichia coli [27]. Moreover, S. epidermidis affects 
the Toll-like keratinocyte receptors, exerting a beneficial 
effect on maintaining the integrity of the skin’s protec-
tive barrier, including the intensification of TJs expres-
sion and proinflammatory cytokine production [10]. AD 
patients manifest a typical skin microbiome abnormality 
– in more than 90% of cases, the skin is colonized by S. 
aureus, while in the healthy population, the percentage 
is close 5% [35]. Polish authors also draw attention to this 
problem [54]. S. aureus colonization and secondary loss 
of skin microbiome versatility in AD patients are facili-
In AD patients, allergens, binding with keratinocyte pat-
tern recognition receptors (PRRs), affect an increased 
release of thymic stromal lymphopoietin (TSLP), IL-25 
and IL-33. They, in turn, induce the release of IL-5 and 
IL-13 by innate lymphoid cells (ILC), intensifying Th2 
type skin inflammation [25, 44, 67]. Additionally, TSLP 
activates dendritic cells, which play the role of antigen 
presenting cells and are responsible for Th2 lymphocyte 
maturation [44]. In keeping with the Th1/Th2 paradigm, 
the key role in allergy development is believed to lie in 
upsetting the balance between the two helper lympho-
cyte populations. Th1-type lymphocytes produce IL-2, 
IL-12 and IFN-γ cytokines, responsible for immunity to 
infectious factors, while Th2 lymphocytes are a source 
of cytokines capable of inducing IgE class antibodies 
production (IL-4 and IL-13) and promoting the develop-
ment of allergic inflammation (interleukins: IL-3, IL-5, 
IL-6, IL-9, IL-13) [36]. Keratinocytes that differentiate in 
the presence of IL-4 and IL-13 demonstrate a decreased 
FLG expression, which suggests that the allergic inflam-
matory response leads to a (acquired) dysfunction of 
the epidermal protective barrier with a decreased FLG 
function [33]⁠. Mechanical trauma, infectious factors and 
exposure to certain allergens also facilitate intensified 
expression of TSLP, IL-25 and IL-33 [46,49] and a shift 
in the balance in favor of Th2-type response [43]. Some 
protease allergens (e.g. house dust mite allergens) pen-
etrate deeper into the epidermal and dermal layers and, 
thanks to their proteolytic effect on occludins, impair 
TJs function [67].
According to the current view, there are three main 
phenotypes of AD: nonlesional skin, acute disease 
flares, and chronic remitting relapsing AD, which cor-
respond to certain types of inflammation, with type 2 
immune response present in all 3 phenotypes, peak-
ing in acute disease flares. TH22-and TH17-driven 
inflammation adds to the type 2 immune response 
Table 2. Examples of environmental exposure on occurrence of particular atopic disorder mediated through epigenetic modifications (based on [31])
Environmental Factor Epigenetic Regulation Clinical phenotype
Allergens (ovalbumin)
Histone deacetylation
Histone acetylation
Allergic asthma, COPD
Allergic asthma
Microbes/farm environment DNA methylation Allergic asthma
Tobacco smoke
DNA methylation
Histone de- and acetylation
COPD
COPD
Folic acid
DNA methylation
Histone acetylation
Allergic asthma
Allergic asthma
Lifestyle (obesity) DNA methylation Allergic asthma
COPD – chronic obstructive pulmonary disease
48
Postepy Hig Med Dosw (online), 2018; tom 72: 43-51
precede respiratory allergy symptoms [19,24]. The results 
of large cohort MAAS and ALSPAC studies indicate that 
the sequence of the allergic march diseases is followed by 
much less than it was previously evaluated. Additionally, 
more than one-half of AD children do not develop any 
subsequent allergic disease [12]. Thus, we are faced with 
the necessity of developing precision medicine which 
would allow us to better define the disease endotypes 
associated with a higher risk of developing asthma 
and allergic rhinitis. Potential candidates may include 
FLG, TSLP, IL-31, IL-33 [24,42,49]. Though opposite 
to respiratory allergies, in AD, due to pathogenetic 
diversity, its phenotypes, endotypes and corresponding 
biomarkers are far less defined, causing the diagnosis 
to remain clinically-based [38]. In the natural course 
of AD, there are two phenotypes that differ in the 
probability of developing coexisting allergic diseases: 
the decidedly more common exogenous type, also 
called “allergic”, associated with an elevated total IgE 
and the presence of specific IgE for environmental and 
food allergens, and the endogenous type, non-allergic, 
without the presence of a specific IgE and with normal 
total IgE [62] (Table 3). The exogenous type is associated 
with the impairment of the protective skin barrier and 
increased allergen penetration, which may lead to the 
so-called transcutaneous allergy [22]. The phenomenon 
was confirmed in individuals with FLG loss-of-function 
mutation, in whom early transcutaneous exposure to 
peanut allergens increased the risk of becoming allergic 
and, in consequence, developing an symptomatic allergy 
to peanuts [14]. A similar phenomenon is seen in other 
food allergies [63,65]. Therefore, the development of 
allergic diseases in distant organs most likely results from 
a systemic response of the immune system to intensified 
allergen penetration through the FLG mutation-impaired 
tated by abnormalities of the epidermal protective barrier 
[10]. Under physiological conditions, FLG decomposi-
tion products inhibit Staphylococcus colonization. In AD 
patients, who manifest decreased levels of FLG, increased 
adhesion and propagation of S. aureus occurs more easily 
[48]. Moreover, AD patients demonstrate a relatively low 
level of AMPs produced by keratinocytes (IL–37 – catheli-
cidin, human beta-defensin – HBD1, HBD2, HBD3), which 
constitute the chemical defense line against skin patho-
gens, especially S. aureus and Herpes simplex viruses 
(HSV [37]. An additional aspect of local inflammatory 
potentiation by S. aureus is its ability to release toxins, 
e.g. staphylococcal enterotoxin B (SEB), which is noted in 
approximately 50% of AD patients [47]. Since SEB acts as a 
superantigen, directly activating Th2 lymphocytes with-
out the contribution of antigen-presenting cells, it thus 
intensifies inflammation and IgE synthesis [47]. In an ani-
mal model [68], with mice transepidermally exposed to 
SEB, systemic Th17/IL-17 reaction and intensified Th2 
reaction were achieved, with secondary inflammatory 
state and respiratory hyperactivity. Also, recent results 
indicate an association between poorer asthma control 
in adults and the presence of staphylococcal entero-
toxin sIgE [57,61]. A significant clinical problem is a lin-
ear increase in the percentage of AD children colonized 
by methicillin-resistant S. aureus (MRSA). A longitudinal 
study (1999-2014) performed in AD children (0-18 years) 
showed a 24-fold increase of MRSA-positive vs. methi-
cillin-sensitive (MSSA) S. aureus and Streptococcus sp. 
results [17].
current vIews on And role In the development of other AtopIc dIseAses
Though AD is a common atopic disease of childhood and 
the most common skin disease in children, it may not 
Table 3. Features of the extrinsic and intrinsic types of atopic dermatitis (based on [62])
Features Extrinsic AD Intrinsic AD
Frequency 80% 20%
Specific IgE Present (especially against house dust mites) Absent
Sensitization Confirmed Absent
Men : Women 1 : 1 1 : 3-4
Onset Early Late
Remission Early Late or  not
FLG mutation Yes No
Disrupted skin barrier Yes No
T-cell polarisation Th1 < Th2 Th1 > Th2
Others:
Severe itching
Eosinophilia
Metal allergy (contact allergy)
An increased risk for asthma and allergic rhinitis Lower risk for asthma and allergic rhinitis
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The concept of the allergic march is not confirmed by 
running results of intervention studies aimed at pre-
venting atopic diseases. At the current stage of research, 
no evidence supports the idea that AD prevention simul-
taneously prevents respiratory tract atopy, while the 
recommended primary prevention methods seem to be 
organ-specific – different for the skin, gastrointestinal 
and respiratory tract. [16,64].
Summarizing the current views on immunopathophy-
siology of AD, we can state that it is a complex dise-
ase with various phenotypes giving rise to variations 
underlying genetic and immunologic patomechanisms, 
as well as an individualized response to pharmacologic 
treatment, which allows us to distinguish subclasses of 
phenotypes termed endotypes. The leading role of AD in 
atopic march might be less pronounced than previously 
expected, as less than 10% of children follow this scena-
rio. Currently, it seems rather to be the coexistance of 
skin and respiratory symptoms, while a cause-and-effect 
relationship seems to be uncertain.
Constantly up-dated guidelines on the treatment of AD, 
endotype-addressed therapeutic intervention, according 
to modern precision medicine, may give AD children a 
greater potential for both better outcome and preven-
tion with respect to respiratory symptoms [1,49,51].
skin barrier [47]. Hypersensitivity and the production 
of specific IgE to inhalant and food allergens in the 
mechanism of transcutaneous sensitization may lead to 
IgE-involving chronic inflammatory diseases, especially 
asthma and AR [6]. In the case of the same allergen, 
the allergy at the skin level precedes the allergy at the 
respiratory tract level [22], which may be associated with 
immune methods-confirmed FLG presence solely in the 
skin epithelial tissue, oral and nasal vestibule, with FLG 
being not detected in bronchial biopsy specimens of the 
respiratory epithelium [47]. Impaired skin barrier by 
FLG-loss of function leads to innate immunity mediated 
inflammation with subsequent progression and acquired 
(secondary) immunological response manifested 
by allergic respiratory symptoms [56]. The above 
phenomena confirm the hypothesis of a ̋ double exposure 
to allergensʺ, where consumption of food allergens 
induces their tolerance, while transcutaneous exposure 
via damaged skin leads to allergy development [40]. This 
view remains in line with the concept of atopic march.
Contrary to the role of an impaired skin barrier in AD, 
a healthy, intact skin barrier allows for treating some 
allergic diseases via epicutaneous immunotherapy (EPI), 
predominantly in the case of food allergens (milk, hen 
egg-white, peanuts) [2,46]. Under normal conditions, 
interactions between the healthy skin barrier allows for 
the proper maturation of the immune system, inducing 
immune tolerance via the transcutaneous route [46].
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